Dr. Alexander Shneider | Source | Founder and CEO at CureLab Oncology

Dr. Alexander Shneider

Founder and CEO at CureLab Oncology
On the record
Represented by:
Share profile 
Bio
Edit

Dr. Shneider is a biotech entrepreneur with over 20 years of comprehensive industry experience. The focus of his work today is the development of a novel biological agent against cancer and diseases of chronic inflammation.

His company’s lead drug ‘Elenagen’ has demonstrated significant safety and clinical benefits in an international Phase II clinical trial. In addition to human medicine, Elenagen shows promise in the treatment of cancers and age-associated inflammatory diseases in cats and dogs.

Dr. Shneider serves as a consultant and advisor for international biotech, pharmaceutical, and investment companies with projects that include R&D, licensing, technology transfer, product and process development to IP, management, and business strategies. He has held professor-level positions at two international universities and serves as an editorial board member at several reputable scientific journals.

Dr. Shneider was one of the pioneers in DNA vaccine industry developing adjuvants and vaccination regiments for preventive anti-infective DNA vaccines. Also, we worked in antiviral drug development (e.g. Dr. Shneider proposed to use melatonin as a part of anti-COVID-19 regiment). Patents to Dr. Shneider’s inventions have been granted in more than 20 countries.

In addition to being a practicing scientist, Dr. Shneider has written fundamental papers in the methodology, history, and evolution of science. One of his papers was initially rejected by 12 journals but went on to become the most-read paper, holding the #1 position in the “Hidden Jewel" category, according to Faculty 1000.

Recent Quotes
Sign up to view all

  • “Almost 1 in 80 women will be diagnosed with ovarian cancer during their lifetime, and almost 1 in 110 will die of it,” said Dr. Alex Shneider, founder and CEO of CureLab Oncology. “I doubt that we can significantly change these numbers anytime soon. But these numbers would be less tragic if we could say to a diagnosed woman: ‘We can give you an extended period of a high-quality life.’ Our team has been focused on giving patients diagnosed with platinum-resistant ovarian cancer additional life — a life full of energy and free of pain.”

  • “Perhaps, gemcitabine is teaching us to be skeptical of the dominant biotech dogma,” said Dr. Alexander Shneider, the primary author of the paper and CureLab’s founder. “In 1971, when President Nixon declared a ‘war on cancer,’ scientists made an honest and probably inevitable mistake: they proposed that new drugs should come from a deeper understanding of the molecular mechanisms of the disease.

    “Thus, it became ‘cool’ for top academic institutions and the most prestigious journals to pursue only mechanism-based drug development, undermining and ignoring the traditional way that brought us most of the life-saving drugs in use today. After five decades and hundreds of billions spent, relatively few drugs have made it to medical practice using the mechanism-based approach. Gemcitabine is a classic example of one of the pitfalls of mechanism-based drug development. What we consider the mechanism of action today may, tomorrow, turn out to be just one of the mechanisms — and maybe not even the most important one.”

  • We live in a time when #grant #funding for many research fields has become extremely sparse. There is little reason to expect the situation to improve significantly in the near future. For many, if not for the majority of scientists funded by #NIH for example, their professional situation is close to “life or death” depending on how their grant application will be reviewed. In turbulent moments like this, it is typical that members of different research communities seek protection in “ #tribalism ”.

Media
Sign up to view all
Employment
Sign up to view all